Tissue content of metalloproteinase-9 and collagen in the colon with and without fecal stream after intervention with infliximab in rats subjected to Hartmann's surgery

• Published in: Acta cirurgica brasileira Vol. 36; no. 4; p. e360401
• Main Authors: Alves Junior, Antonio José Tiburcio, Pereira, José Aires, Ávila, Mariane Grandi de, Domingues, Fernanda Aparecida, Sato, Daniela Tiemi, Martinez, Carlos Augusto Real
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 01-01-2021
• Subjects: Animals; Colitis; Collagen; Colon - surgery; Free Oxygen Radicals; Infliximab; Intestinal Mucosa; Matrix Metalloproteinase 9; Metalloproteases; Original; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Volatile Fatty Acids
• ISSN: 0102-8650; 1678-2674
• DOI: 10.1590/ACB360401

Quantify the tissue content of metalloproteinase-9 (MMP-9) and collagen in colic mucosa with and without intestinal transit after infliximab administration in rats subjected to Hartmann's surgery.
Twenty-two rats underwent colon diversion by Hartmann's surgery. Animals were maintained with intestinal bypass for 12 weeks to induce development of diversion colitis (DC). Afterwards, animals were divided into three groups: first group received subcutaneous application of saline solution (SS) 0.9%, while the remaining two groups received infliximab subcutaneously at doses of 5 or 10 mg·kg-1·week-1 for five consecutive weeks. After the intervention, animals were sacrificed, removing the segments with and without intestinal transit. Diversion colitis was diagnosed by histological study, and its intensity was determined by a validated inflammatory scale. Tissue expression of MMP-9 was assessed byimmunohistochemistry, while total collagen was assessed by histochemistry. Tissue content of both was measuredby computerized morphometry.
Colon segments without intestinal transit had a higher degree of inflammation, which improved in animals treated with infliximab. Collagen content was always lower in those without intestinal transit. There was an increase in the collagen content in the colon without transit in animals treated with infliximab, primarily at a dose of 10 mg·kg-1·week-1. There was an increase in the content of MMP-9 in the colon without fecal transit, and a reduction was observed in animals treated with infliximab, regardless of the dose used.
Application of infliximab reduces inflammation, increases the total collagen content and decreases the content of MMP-9 in the colon without intestinal transit.